Pearl River Capital’s Immunovant IMVT Stock Holding History

Pearl River Capital’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-26,053	Closed	-$842K	–	517
2024 Q1	$842K	Buy	+26,053	New	+$950K	0.13%	221

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AGM

Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Pearl River Capital's IMVT Position: Q2 2024 in Review

Pearl River Capital sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 26,053 shares — an estimated $842K sold.

Pearl River Capital first reported a position in IMVT in Q1 2024 and held it in 1 quarter. The position peaked at $842K in Q1 2024. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

Pearl River Capital reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
Pearl River Capital sold 26,053 Immunovant shares in Q2 2024, an estimated $842K.
Pearl River Capital first reported a position in Immunovant in Q1 2024 and held it in 1 quarter.
Pearl River Capital's Immunovant position peaked at $842K in Q1 2024.
197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Pearl River Capital's 13F filing for Q2 2024, filed 13 Aug 2024.